Monoamine oxidase b: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 39: | Line 39: | ||
The connection between MAO-B and diseases like Parkinson’s and Alzheimer’s has promoted the development of medicinal inhibitors for this flavoenzyme. L-dopa therapy, which uses l-deprenyl, is just one of the medications developed for MAO-B inhibition. The long-term effectiveness of L-dopa and other proposed medications is not fully characterized. As of now, research has focused on compounds similar in structure to known inhibitors. A range of inhibitors, reversible and irreversible, are known. Evaluation of how the inhibition affects patients should continue to be conducted in order to study the effectiveness of the developed inhibitors. | The connection between MAO-B and diseases like Parkinson’s and Alzheimer’s has promoted the development of medicinal inhibitors for this flavoenzyme. L-dopa therapy, which uses l-deprenyl, is just one of the medications developed for MAO-B inhibition. The long-term effectiveness of L-dopa and other proposed medications is not fully characterized. As of now, research has focused on compounds similar in structure to known inhibitors. A range of inhibitors, reversible and irreversible, are known. Evaluation of how the inhibition affects patients should continue to be conducted in order to study the effectiveness of the developed inhibitors. | ||
==3D structures of monoamine oxidase== | |||
[[Monoamine oxidase]] | |||
==Additional Resources== | ==Additional Resources== | ||